Cancer Research and Treatment

Hyo Seop Ahn

12 Articles

Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients: Hyery Kim, Hyoung Jin Kang, Kyung Duk Park, Kyung-Nam Koh, Ho Joon Im, Jong Jin Seo, Jae Wook Lee, Nack-Gyun Chung, Bin Cho, Hack Ki Kim, Jae Min Lee, Jeong Ok Hah, Jun Ah Lee, Young Ho Lee, Sang Kyu Park, Hee Jo Baek, Hoon Kook, Ji Yoon Kim, Heung Sik Kim, Hwang Min Kim, Hee Won Chueh, Meerim Park, Hoi Soo Yoon, Mee Jeong Lee, Hyoung Soo Choi, Hyo Seop Ahn, Yoshifumi Kawano, Ji Won Park, Seokyung Hahn, Hee Young Shin; Cancer Res Treat. 2019;51(1):357-367. Published online May 14, 2018; DOI: https://doi.org/10.4143/crt.2017.457

Abstract PDF Supplementary Material PubReader ePub

Purpose
Dexrazoxane has been used as an effective cardioprotector against anthracycline cardiotoxicity. This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies in dexrazoxane-treated pediatric patients.
Materials and Methods
Data was collected from 15 hospitals in Korea. Patients who received any anthracyclines, and completed treatment without stem cell transplantation were included. For efficacy evaluation, the incidence of cardiac events and cardiac event-free survival rates were compared. Data about risk factors of secondary malignancies were collected.
Results
Data of total 1,453 cases were analyzed; dexrazoxane with every anthracyclines group (D group, 1,035 patients) and no dexrazoxane group (non-D group, 418 patients). Incidence of the reported cardiac events was not statistically different between two groups; however, the cardiac event-free survival rate of patients with more than 400 mg/m² of anthracyclines was significantly higher in D group (91.2% vs. 80.1%, p=0.04). The 6-year cumulative incidence of secondary malignancy was not different between both groups after considering follow-up duration difference (non-D, 0.52%±0.37%; D, 0.60%±0.28%; p=0.55). The most influential risk factor for secondary malignancy was the duration of anthracycline administration according to multivariate analysis.
Conclusion
Dexrazoxane had an efficacy in lowering cardiac event-free survival rates in patients with higher cumulative anthracyclines. As a result of multivariate analysis for assessing risk factors of secondary malignancy, the occurrence of secondary malignancy was not related to dexrazoxane administration.

Citations

Citations to this article as recorded by

Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage
Veronika Keresteš, Jan Kubeš, Lenka Applová, Petra Kollárová, Olga Lenčová-Popelová, Iuliia Melnikova, Galina Karabanovich, Mushtaq M Khazeem, Hana Bavlovič-Piskáčková, Petra Štěrbová-Kovaříková, Caroline A Austin, Jaroslav Roh, Martin Štěrba, Tomáš Šimůn
Toxicological Sciences.2024; 198(2): 288. CrossRef
Circ-0006332 stimulates cardiomyocyte pyroptosis via the miR-143/TLR2 axis to promote doxorubicin-induced cardiac damage
Ping Zhang, Yuanyuan Liu, Yuliang Zhan, Pengtao Zou, Xinyong Cai, Yanmei Chen, Liang Shao
Epigenetics.2024;[Epub] CrossRef
Pediatric Cardio-Oncology: Screening, Risk Stratification, and Prevention of Cardiotoxicity Associated with Anthracyclines
Xiaomeng Liu, Shuping Ge, Aijun Zhang
Children.2024; 11(7): 884. CrossRef
Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines
Parya Rahimi, Behsheed Barootkoob, Ahmed ElHashash, Arun Nair
Cureus.2023;[Epub] CrossRef
Inducing a Proinflammatory Response with Bioengineered Yeast Vacuoles with TLR2-Binding Peptides (VacT2BP) as a Drug Carrier for Daunorubicin Delivery
Wooil Choi, Woo-Ri Shin, Yang-Hoon Kim, Jiho Min
ACS Applied Materials & Interfaces.2023; 15(35): 41258. CrossRef
Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children
Luigia Meo, Maria Savarese, Carmen Munno, Peppino Mirabelli, Pia Ragno, Ornella Leone, Mariaevelina Alfieri
Pharmaceutics.2023; 15(12): 2712. CrossRef
Hyperhomocysteinemia as a Link of Chemotherapy-Related Endothelium Impairment
Ashot Avagimyan
Current Problems in Cardiology.2022; 47(10): 100932. CrossRef
Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group
Eric J. Chow, Richard Aplenc, Lynda M. Vrooman, David R. Doody, Yuan‐Shung V. Huang, Sanjeev Aggarwal, Saro H. Armenian, K. Scott Baker, Smita Bhatia, Louis S. Constine, David R. Freyer, Lisa M. Kopp, Wendy M. Leisenring, Barbara L. Asselin, Cindy L. Schw
Cancer.2022; 128(4): 788. CrossRef
Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Esmée C de Baat, Elvira C van Dalen, Renée L Mulder, Melissa M Hudson, Matthew J Ehrhardt, Frederike K Engels, Elizabeth A M Feijen, Heynric B Grotenhuis, Jan M Leerink, Livia Kapusta, Gertjan J L Kaspers, Remy Merkx, Luc Mertens, Roderick Skinner, Wim J
The Lancet Child & Adolescent Health.2022; 6(12): 885. CrossRef
Cardiotoxicity After Anthracycline Chemotherapy for Childhood Cancer in a Multiethnic Asian Population
Varen Zhi Zheng Tan, Nicole Min Chan, Wai Lin Ang, Soe Nwe Mya, Mei Yoke Chan, Ching Kit Chen
Frontiers in Pediatrics.2021;[Epub] CrossRef
Early-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study
Adriana Linares Ballesteros, Roy Sanguino Lobo, Juan Camilo Villada Valencia, Oscar Arévalo Leal, Diana Constanza Plazas Hernández, Nelson Aponte Barrios, Iván Perdomo Ramírez
Colombia Medica.2021; 52(1): e2034542. CrossRef
Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy
Claire Fraley, Sarah A. Milgrom, Lavanya Kondapalli, Matthew R. G. Taylor, Luisa Mestroni, Shelley D. Miyamoto
Children.2021; 8(9): 829. CrossRef
Dantrolene Attenuates Cardiotoxicity of Doxorubicin Without Reducing its Antitumor Efficacy in a Breast Cancer Model
Valentina K. Todorova, Eric R. Siegel, Yihong Kaufmann, Asangi Kumarapeli, Aaron Owen, Jeanne Y. Wei, Issam Makhoul, V. Suzanne Klimberg
Translational Oncology.2020; 13(2): 471. CrossRef
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity
Petra Kollárová-Brázdová, Anna Jirkovská, Galina Karabanovich, Zuzana Pokorná, Hana Bavlovič Piskáčková, Eduard Jirkovský, Jan Kubeš, Olga Lenčová-Popelová, Yvona Mazurová, Michaela Adamcová, Veronika Skalická, Petra Štěrbová-Kovaříková, Jaroslav Roh, Tom
The Journal of Pharmacology and Experimental Therapeutics.2020; 373(3): 402. CrossRef
Anthracyclines/cyclophosphamide/etoposide

Reactions Weekly.2019; 1741(1): 28. CrossRef
Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case series
Sarju Ganatra, Anju Nohria, Sachin Shah, John D. Groarke, Ajay Sharma, David Venesy, Richard Patten, Krishna Gunturu, Corrine Zarwan, Tomas G. Neilan, Ana Barac, Salim S. Hayek, Sourbha Dani, Shantanu Solanki, Syed Saad Mahmood, Steven E. Lipshultz
Cardio-Oncology.2019;[Epub] CrossRef
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
Neha Bansal, M. Jacob Adams, Sarju Ganatra, Steven D. Colan, Sanjeev Aggarwal, Rudolf Steiner, Shahnawaz Amdani, Emma R. Lipshultz, Steven E. Lipshultz
Cardio-Oncology.2019;[Epub] CrossRef
Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies – Part 2
Antonis A. Manolis, Theodora A. Manolis, Dimitri P. Mikhailidis, Antonis S. Manolis
Expert Opinion on Drug Safety.2018; 17(9): 893. CrossRef

10,482 View
334 Download
19 Web of Science
18 Crossref

ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor: Ji Won Lee, Sung Hye Park, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Hyo Seop Ahn; Cancer Res Treat. 2018;50(2):495-505. Published online May 22, 2017; DOI: https://doi.org/10.4143/crt.2016.577

Abstract PDF PubReader ePub

Purpose
In this study, anaplastic lymphoma kinase (ALK) mutation and amplification, ALK protein expression, loss of the nuclear alpha thalassemia/mental retardation syndrome X-linked (ATRX) protein, and telomerase reverse transcriptase (TERT) protein expressionwere studied to investigate potential correlations between these molecular characteristics and clinical features or outcomes in neuroblastoma.
Materials and Methods
Seventy-two patients were enrolled in this study. Polymerase chain reaction amplification and direct sequencing were used for mutation analysis. ALK and MYCN amplifications were detected by fluorescence in situ hybridization. Protein expressionwas evaluated by immunohistochemical (IHC) staining.
Results
ALK mutation was found in only two patients (4.1%); ALK amplification was not detected. ALK positivity, loss of nuclear ATRX protein, TERT positivity by IHC were detected in 40 (55.6%), nine (13.0%), and 42 (59.2%) patients, respectively. The incidence of ALK expression increased in accordance with increasing tumor stage (p=0.001) and risk group (p < 0.001). The relapse rate was significantly higher in ALK⁺ patients compared to that of other patients (47.5% vs. 11.3%, p=0.007). However, there was no significant difference in relapse rate when the survival analysis was confined to the high-risk patients.
Conclusion
Although ALK mutation was rare and no amplification was observed, ALK protein expression was found in a significant number of patients and was correlated with advanced stage and high-risk neuroblastoma. ALK protein expression could be considered as a marker related to the aggressive neuroblastoma, but it was not the independent prognostic factor for the outcome.

Citations

Citations to this article as recorded by

Immunohistochemical expression of anaplastic lymphoma kinase in neuroblastoma and its relations with some clinical and histopathological features
Thu Dang Anh Phan, Thao Quyen Nguyen, Nhi Thuy To, Thien Ly Thanh, Dat Quoc Ngo
Journal of Pathology and Translational Medicine.2024; 58(1): 29. CrossRef
Multi-omics revealed that ELAVL3 regulates MYCN in neuroblastoma via immunogenic cell death: Risk stratification and experimental research
Peng Hong, Zaihong Hu, Jie Lin, Kongkong Cui, Zhiqiang Gao, Xiaomao Tian, Qinlin Shi, Tao Lin, Guanghui Wei
International Journal of Biological Macromolecules.2024; 282: 137045. CrossRef
Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in MYCN Non-Amplified Neuroblastoma
Manli Zhao, Weizhong Gu, Fei Liu, Lihua Yu, Yan Shu, Lei Liu, Jiahui Hu, Yang Liu, Hongfeng Tang, Jianhua Mao
Pediatric and Developmental Pathology.2023; 26(2): 124. CrossRef
ALKGene Mutation and ALK Protein Expression in Advanced Neuroblastoma and the Potential Value in Risk Stratification in Fine-Needle Aspiration Biopsy Samples
Neha Bhardwaj, Manish Rohilla, Upasana Gautam, Amita Trehan, Deepak Bansal, Nandita Kakkar, Radhika Srinivasan
American Journal of Clinical Pathology.2023;[Epub] CrossRef
Rapid detection of telomerase expression of neuroblastoma in paraffin-embedded tissue: combination of in situ hybridisation and quantitative PCR
Manli Zhao, Zhonghai Guan, Liang Gong, Fei Liu, Weizhong Gu, Lei Liu, Kewen Jiang, Jiabin Cai, Chunyue Feng, Chik Hong Kuick, Kenneth Tou En Chang, Jinhu Wang, Hongfeng Tang, Minzhi Yin, Jianhua Mao
Pathology.2023; 55(7): 958. CrossRef
Interactions of Butyrylcholinesterase with Neuroblastoma-associated Oncoproteins
Janina Baranowska-Kortylewicz, Zbigniew P. Kortylewicz, Erin M. McIntyre, John G. Sharp, Don W. Coulter
Current Enzyme Inhibition.2023; 19(2): 109. CrossRef
Combined Detection of Copy Number Variations of MYCN and ALK using Droplet Digital Polymerase Chain Reaction to Identify High-Risk Patients with Neuroblastoma
Trupti Trivedi, Kinjal Panchal, Neha Bhalala, Priti Trivedi, Harsha Panchal
World Neurosurgery.2022; 159: e48. CrossRef
ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma
Dinesh Babu Somasundaram, Sheeja Aravindan, Nandita Gupta, Zhongxin Yu, Ashley Baker, Natarajan Aravindan
World Journal of Pediatrics.2022; 18(4): 285. CrossRef
Multifarious Functions of Butyrylcholinesterase in Neuroblastoma: Impact of BCHE Deletion on the Neuroblastoma Growth In Vitro and In Vivo
Janina Baranowska-Kortylewicz, Zbigniew P. Kortylewicz, Erin M. McIntyre, John G. Sharp, Don W. Coulter
Journal of Pediatric Hematology/Oncology.2022; 44(6): 293. CrossRef
Differential Impact of ALK Mutations in Neuroblastoma
Tara O'Donohue, Nitya Gulati, Audrey Mauguen, Brian H. Kushner, Neerav Shukla, M. I. Rodriguez-Sanchez, Nancy Bouvier, Stephen Roberts, Ellen Basu, Nai-Kong Cheung, Shakeel Modak
JCO Precision Oncology.2021; (5): 492. CrossRef
The challenge of defining “ultra‐high‐risk” neuroblastoma
Daniel A. Morgenstern, Rochelle Bagatell, Susan L. Cohn, Michael D. Hogarty, John M. Maris, Lucas Moreno, Julie R. Park, Andrew D. Pearson, Gudrun Schleiermacher, Dominique Valteau‐Couanet, Wendy B. London, Meredith S. Irwin
Pediatric Blood & Cancer.2019;[Epub] CrossRef
ALK in Neuroblastoma: Biological and Therapeutic Implications
Ricky Trigg, Suzanne Turner
Cancers.2018; 10(4): 113. CrossRef

10,162 View
364 Download
10 Web of Science
12 Crossref

Clinical Results of Chemotherapy based Treatment in Retinoblastoma Patients: A Single Center Experience: Hyery Kim, Ji Won Lee, Hyoung Jin Kang, Hyeon Jin Park, Yoon Yi Kim, Hee Young Shin, Young Suk Yu, Il Han Kim, Hyo Seop Ahn; Cancer Res Treat. 2008;40(4):164-171. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.164

Abstract PDF PubReader ePub

Purpose

Retinoblastoma is the most common intraocular malignancy in children. Since the 1990s, chemotherapy was indicated for intraocluar disease to reduce the frequency of enucleation and spare the complications associated with external beam radiation. In this study, we analyzed treatment results of retinoblastoma in our institute.

Materials and Methods

Datas from children diagnosed with retinoblastoma and treated at Seoul National University Children's Hospital between 1986 and 2008 were analyzed retrospectively. We utilized cyclophosphamide, vincristine, adriamycin, and methotrexate (CVAM) for OPD-based adjuvant chemotherapy. From 1990, primary chemotherapy was administered to patients with intraocular disease for eyeball-saving and patients received a combination of etoposide, vincristine, cisplatin (or ifosfamide) as a moderately intensive regimen, or a combination of cisplatin, doxorubicin, etoposide, and cycophosphamide (CDEC) as a highly intensive regimen.

Results

One hundred eighteen children were analyzed. There were 68 unilateral and 50 bilateral diseases. The median age at diagnosis was 1 year and Reese-Ellsworth stage V was the most common stage at the time of diagnosis. All patients were treated by chemotherapy-based multimodality methods, and primary chemotherapy was administered to 80 patients. The 10-year overall and event-free survival rate of all patients were 93.9% and 91.6%, respectively. Two patients who died were in the CDEC regimen group, but there was no significant statistical difference in survival rates by chemotherapy regimens. Fifty-six of 114 eyeballs were saved after primary chemotherapy-based treatment, and the eyeball-saving rate was 49.1%. Six patients relapsed after enucleation and 2 patients were treated successfully after autologous PBSCT. Osteosarcoma occurred in 2 patients as a secondary malignancy, and facial asymmetry after radiotherapy was the most common long-term sequelae.

Conclusions

In this study, the overall and event-free survival rates of retinoblastoma were satisfactory and eye-saving was possible with primary chemotherapy. Development of new chemotherapeutic regimens and a team approach are necessary to improve the eyeball-saving rate.

Citations

Citations to this article as recorded by

The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases
Chiara Crotti, Nicola Ughi, Emanuela Beretta, Antonio Luca Brucato, Greta Carrara, Maria Sole Chimenti, Paola Conigliaro, Francesca Crisafulli, Giovanna Cuomo, Emma Di Poi, Khadija El Auofy, Micaela Fredi, Maria Chiara Gerardi, Maria Gerosa, Ariela Hoxa,
Reumatismo.2025;[Epub] CrossRef
The Efficacy of Alternate Systemic Intravenous Chemotherapy and Intra-arterial Chemotherapy Approach for Eye Globe Salvage in Retinoblastoma
Jung Woo Han, Christopher Seungkyu Lee, Seung Min Hahn, Won Kee Ahn, Hyo Sun Kim, Hyeseon Yun, Sung Chul Lee, Byung Moon Kim, Dong Joon Kim, Chuhl Joo Lyu
Cancer Research and Treatment.2023; 55(1): 270. CrossRef
Global retinoblastoma survival and globe preservation: a systematic review and meta-analysis of associations with socioeconomic and health-care factors
Emily S Wong, Richard W Choy, Yuzhou Zhang, Wai Kit Chu, Li Jia Chen, Chi Pui Pang, Jason C Yam
The Lancet Global Health.2022; 10(3): e380. CrossRef
Twenty-Year Retrospective Study of Post-Enucleation Chemotherapy in High-Risk Patients with Unilateral Retinoblastoma
Yoon Sunwoo, Jung Yoon Choi, Hyun Jin Park, Bo Kyung Kim, Kyung Taek Hong, Sang In Khwarg, Jaemoon Koh, Sung-Hye Park, Dong Hyun Jo, Jeong Hun Kim, Jung-Eun Cheon, Hyoung Jin Kang
Children.2022; 9(12): 1983. CrossRef
Development of New Solitary Retinoblastoma Tumors during and after Chemotherapy
Won Jong Choi, Dong Hyun Jo, Hyoung Jin Kang, Hee Young Shin, Young Suk Yu, Jeong Hun Kim
Korean Journal of Ophthalmology.2021; 35(1): 73. CrossRef
Outcomes of pediatric retinoblastoma treated with ICEV regimen: A single-center study
Jassada Buaboonnam, Nattee Narkbunnam, Nassawee Vathana, Chayamon Takpradit, Kamon Phuakpet, Bunchoo Pongtanakul, Sasima Tongsai, La-Ongsri Atchaneeyasakul, Kleebsabai Sanpakit
Pediatric Hematology and Oncology.2019; 36(2): 73. CrossRef
Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”
Francis L. Munier, Maja Beck-Popovic, Guillermo L. Chantada, David Cobrinik, Tero T. Kivelä, Dietmar Lohmann, Philippe Maeder, Annette C. Moll, Angel Montero Carcaboso, Alexandre Moulin, Paula Schaiquevich, Ciara Bergin, Paul J. Dyson, Susan Houghton, Fra
Progress in Retinal and Eye Research.2019; 73: 100764. CrossRef
Outcomes of Proton Beam Radiation Therapy for Retinoblastoma With Vitreous Seeds
Eun Hye Jung, Jeong Hun Kim, Joo Young Kim, Dong Hyun Jo, Young Suk Yu
Journal of Pediatric Hematology/Oncology.2018; 40(8): 569. CrossRef
Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress
Zeren Shen, Jinjin Shao, Jiabin Dai, Yuchen Lin, Xiaochun Yang, Jian Ma, Qiaojun He, Bo Yang, Ke Yao, Peihua Luo
Toxicology Reports.2016; 3: 78. CrossRef
Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma
Seung Min Hahn, Hyo Sun Kim, Dong Joon Kim, Sung Chul Lee, Chuhl Joo Lyu, Jung Woo Han
Pediatric Hematology and Oncology.2016; 33(1): 74. CrossRef
Diagnosis & Treatment of Retinoblastoma: Current Review
Heewon Chueh
Clinical Pediatric Hematology-Oncology.2015; 22(1): 38. CrossRef
High‐dose chemotherapy with autologous stem cell rescue for treatment of retinoblastoma: Report of five cases
Désirée Caselli, Angela Tamburini, Agostino La Torre, Liliana Pollazzi, Veronica Tintori, Franco Bambi, Roberto Caputo, Maurizio Aricò
Pediatric Transplantation.2014; 18(6): 631. CrossRef
Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments
Carlo Venturi, Sandra Bracco, Alfonso Cerase, Samuele Cioni, Paolo Galluzzi, Paola Gennari, Ignazio M. Vallone, Rebecca Tinturini, Cesare Vittori, Sonia De Francesco, Mauro Caini, Alfonso D’Ambrosio, Paolo Toti, Alessandra Renieri, Theodora Hadjistilianou
Acta Ophthalmologica.2013; 91(4): 335. CrossRef
Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma
Aman Khurana, Christina A. Eisenhut, Wenshuai Wan, Katayoon B. Ebrahimi, Chirag Patel, Joan M. O’Brien, Kristen Yeom, Heike E. Daldrup-Link
European Radiology.2013; 23(5): 1271. CrossRef
Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells
HYUN BEOM SONG, HYOUNG-OH JUN, JIN HYOUNG KIM, YOUNG SUK YU, KYU-WON KIM, BON HONG MIN, JEONG HUN KIM
Oncology Reports.2013; 30(6): 2713. CrossRef
Combined Treatment with an Oncolytic Adenovirus and Antitumor Activity of Vincristine against Retinoblastoma Cells
Xin Song, Haibo Wang, Renbing Jia, Biyun Cun, Xiaoping Zhao, Yixiong Zhou, Xiaofang Xu, Guanxiang Qian, Shengfang Ge, Xianqun Fan
International Journal of Molecular Sciences.2012; 13(9): 10736. CrossRef
Long Term Follow-up Results of External Beam Radiotherapy as Primary Treatment for Retinoblastoma
Sang Yul Choi, Mi-Sook Kim, SungYul Yoo, ChulKoo Cho, YoungHoon Ji, KumBae Kim, YoungSeok Seo, Kyung Duk Park, JunAh Lee, Tai-Won Lee
Journal of Korean Medical Science.2010; 25(4): 546. CrossRef

12,213 View
85 Download
17 Crossref

Clinical Characteristics and Treatment Results of Pediatric Osteosarcoma: The Role of High Dose Chemotherapy with Autologous Stem Cell Transplantation: Ji Won Lee, Hyery Kim, Hyoung Jin Kang, Han-Soo Kim, Sung-Hye Park, In-One Kim, Hyo Seop Ahn, Hee Young Shin; Cancer Res Treat. 2008;40(4):172-177. Published online December 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.4.172

Abstract PDF PubReader ePub

Purpose

In this study, we investigated the clinical characteristics and treatment results of osteosarcoma during the past 7 years, and evaluated the role of high dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT).

Materials and Methods

We retrospectively analyzed the clinical data of patients who were diagnosed as osteosarcoma at our center from January, 2000 to December, 2007.

Results

The 5-year overall survival and event-free survival of the patients were 72.6% and 55.9%, respectively. Seventeen (41.5%) patients showed disease progression during treatment or relapse after the end of treatment. The patients who had metastasis at diagnosis or who had a lower grade of necrosis after neoadjuvant chemotherapy showed decreased overall and event-free survival. Four patients received ASCT after HDCT, and 3 of them are alive without disease.

Conclusions

The patients who relapsed or had refractory osteosarcoma or who had metastasis at diagnosis or a lower grade of necrosis after neoadjuvant chemotherapy showed poor prognosis. HDCT with ASCT could be an alternative treatment option for these patients.

Citations

Citations to this article as recorded by

High‐dose chemotherapy followed by autologous stem cell transplantation in pediatric patients with relapsed osteosarcoma
Sung Han Kang, Wanlim Kim, Jong Seok Lee, Jin Kyung Suh, Hyery Kim, Dong Kwan Kim, Se Hoon Choi, Hee Won Cho, Hee Young Ju, Keon Hee Yoo, Ki Woong Sung, Hong Hoe Koo, Sung Wook Seo, Ho Joon Im, Ji Won Lee, Kyung‐Nam Koh
Pediatric Blood & Cancer.2023;[Epub] CrossRef
Favorable outcome of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with nonmetastatic osteosarcoma and low-degree necrosis
Kyung Taek Hong, Hyun Jin Park, Bo Kyung Kim, Hong Yul An, Jung Yoon Choi, Jung-Eun Cheon, Sung-Hye Park, Han-Soo Kim, Hyoung Jin Kang
Frontiers in Oncology.2022;[Epub] CrossRef
The Outcome of Children With Malignant Bone Tumors: A Single-Center Experience
Mohammadreza Bordbar, Ali Sarfaraz, Sezaneh Haghpanah, Omidreza Zekavat, Soheila Zareifar, Tahereh Zarei
Global Pediatric Health.2021;[Epub] CrossRef
1
L.V. Hryvkova
Practical oncology.2021; 4(1): 30. CrossRef
Retrospective analysis of high-dose chemotherapy followed by autologous stem cell transplantation for high-risk pediatric osteosarcoma
Suguru Uemura, Takeshi Mori, Shinya Ishiko, Satoru Takafuji, Nanako Nino, Nobuyuki Yamamoto, Akira Hayakawa, Noriyuki Nishimura, Hitomi Hara, Teruya Kawamoto, Toshihiro Akisue, Kazumoto Iijima
Pediatric Hematology and Oncology.2020; 37(4): 337. CrossRef
Pulmonary tuberculosis mimicking radiation pneumonitis in a patient with neck malignancy
Kyungsoo Bae, Kyung Nyeo Jeon, Hoon Sik Choi, Dae Hyun Song, Ho Cheol Kim
Medicine.2019; 98(27): e16398. CrossRef
High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma
C R Hong, H J Kang, M S Kim, H Y Ju, J W Lee, H Kim, H-S Kim, S-H Park, K D Park, J D Park, H Y Shin, H S Ahn
Bone Marrow Transplantation.2015; 50(10): 1375. CrossRef
High‐dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study
Kjetil Boye, Adalberto Brach Del Prever, Mikael Eriksson, Gunnar Sæter, Amelia Tienghi, Paula Lindholm, Franca Fagioli, Sigmund Skjeldal, Stefano Ferrari, Kirsten Sundby Hall
Pediatric Blood & Cancer.2014; 61(5): 840. CrossRef
LY294002 suppresses the malignant phenotype and sensitizes osteosarcoma cells to pirarubicin chemotherapy
XIN HUA LONG, ZHEN HAO ZHONG, AI FEN PENG, LIANG BO ZHU, HENG WANG, GUO MEI ZHANG, ZHI LI LIU
Molecular Medicine Reports.2014; 10(6): 2967. CrossRef
Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma
Colin Moore, Don Eslin, Alejandro Levy, Jessica Roberson, Vincent Giusti, Robert Sutphin
Pediatric Blood & Cancer.2010; 55(6): 1096. CrossRef
Cryoimmunologic Antitumor Effects Enhanced by Dendritic Cells in Osteosarcoma
Masanori Kawano, Hideji Nishida, Yasunari Nakamoto, Hiroshi Tsumura, Hiroyuki Tsuchiya
Clinical Orthopaedics and Related Research®.2010; 468(5): 1373. CrossRef

10,486 View
67 Download
11 Crossref

Initial Response to Treatment was Highly Associated with the Prognosis of Childhood Rhabdomyosarcoma: A Retrospective Analysis of a Single Center Experience in Korea: Jeong A Park, Eun Kyung Kim, Hyoung Jin Kang, Hee Young Shin, Il Han Kim, Hyo Seop Ahn; Cancer Res Treat. 2008;40(3):111-115. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.111

Abstract PDF PubReader ePub

Purpose

Following the introduction of a multimodal approach to diagnosis and treatment, the prognosis of rhabdomyosarcoma (RMS) has markedly improved over the last three decades. However, there are few data on treatment outcomes in Korean patients.

Materials and Methods

We performed a retrospective analysis of 77 patients with RMS diagnosed and treated at Seoul National University Children's Hospital between 1986 and 2005.

Results

The overall 5-year survival and event-free survival rates for all patients were 77% and 59%, respectively. The Intergroup Rhabdomyosarcoma Study clinical grouping and initial response to treatment (20-week response) were important prognostic factors.

Conclusions

The outcome of childhood RMS was closely associated with the initial staging and the initial response to treatment. Modulating therapies according to initial responses and risk factors is critical, and new treatment strategies for high-risk patients are needed.

Citations

Citations to this article as recorded by

Adherence to Treatment, Response and Patterns of Failure in Pediatric Parameningeal Rhabdomyosarcoma: Experience From a Tertiary Cancer Care Center From India
Soumyajit Roy, Sushmita Pathy, Bidhu K. Mohanti, Subhash Chander, Ahitagni Biswas
Journal of Pediatric Hematology/Oncology.2017; 39(2): e62. CrossRef
Pediatric rhabdomyosarcoma in India: A single-center experience
Deepak Bansal, Anirban Das, Amita Trehan, Rakesh Kapoor, Naresh K. Panda, Radhika Srinivasan, Nandita Kakkar, Kushaljit S. Sodhi, Akshay K. Saxena, Katragadda Lakshmi Narasimha Rao
Indian Pediatrics.2017; 54(9): 735. CrossRef
The impact of radiotherapy on clinical outcomes in parameningeal rhabdomyosarcoma
Yunseon Choi, Do Hoon Lim
Radiation Oncology Journal.2016; 34(4): 290. CrossRef
Rhabdomyosarcoma Treatment and Outcome at a Multidisciplinary Pediatric Cancer Center in Lebanon
Maysaa Salman, Hani Tamim, Fouad Medlej, Tarek El-Ariss, Fatima Saad, Fouad Boulos, Toufic Eid, Samar Muwakkit, Nabil Khoury, Miguel Abboud, Raya Saab
Pediatric Hematology and Oncology.2012; 29(4): 322. CrossRef
Solid tumours of childhood
Bruce O. Okoye
Surgery (Oxford).2010; 28(8): 382. CrossRef
Primary meningeal rhabdomyosarcoma associated with chronic subdural effusion
Ji Yeoun Lee, Bo Sung Kim, Ji Hoon Phi, Hyoung Jin Kang, Sung-Hye Park, Kyu-Chang Wang, Il Han Kim, Byung-Kyu Cho, Seung-Ki Kim
Journal of Neurosurgery: Pediatrics.2010; 5(2): 167. CrossRef

10,407 View
38 Download
6 Crossref

Carboxypeptidase-G2 Rescue in a Patient with High Dose Methotrexate-induced Nephrotoxicity: Eun Sil Park, Kyung Hee Han, Hyoung Soo Choi, Hee Young Shin, Hyo Seop Ahn; Cancer Res Treat. 2005;37(2):133-135. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.133

Abstract PDF PubReader ePub

A 13 year-old girl with osteosarcoma and pulmonary tumor recurrence developed acute renal failure following high dose methotrexate (12 g/m²) therapy, she had previously tolerated high dose methotrexate and her renal and hepatic functions were normal. Briefly, 48 hours after beginning methotrexate infusion her methotrexate concentration and creatinine level were 1338.8 µM/L and 5.8 mg/dl, respectively. Grade IV oral mucositis and neutropenia with fever developed at 144 hours after MTX infusion. Hydration and alkalinization were continued and leucovorin rescue was intensified based on the plasma MTX concentrations. Plasma exchange was performed twice and hemodialysis 3 times without problems, but methotraxate and creatinine levels remained high, 91.9 µM/L, and 2.5 mg/dl, respectively. After 3 courses of hemodialysis carboxypeptidase-G2 (CPDG2) was administered at 50 U/kg, intravenously over 5 minutes. After 15 minutes of CPDG2 (Voraxaze™) infusion, her plasma MTX concentration was 0.91 µM/L and no rebound elevation or side effects developed. Thirteen days post-MTX infusion her renal function had normalized. We report here our experience of a dramatic methotrexate level reduction caused by CPDG2 administration.

Citations

Citations to this article as recorded by

Extracorporeal Treatment for Methotrexate Poisoning
Marc Ghannoum, Darren M. Roberts, David S. Goldfarb, Jesper Heldrup, Kurt Anseeuw, Tais F. Galvao, Thomas D. Nolin, Robert S. Hoffman, Valery Lavergne, Paul Meyers, Sophie Gosselin, Tudor Botnaru, Karine Mardini, David M. Wood
Clinical Journal of the American Society of Nephrology.2022; 17(4): 602. CrossRef
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients
Jeffrey R. Scott, Yinmei Zhou, Cheng Cheng, Deborah A. Ward, Hope D. Swanson, Alejandro R. Molinelli, Clinton F. Stewart, Fariba Navid, Sima Jeha, Mary V. Relling, Kristine R. Crews
Pediatric Blood & Cancer.2015; 62(9): 1518. CrossRef
Resumption of high‐dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients
Anthony M. Christensen, Jennifer L. Pauley, Alejandro R. Molinelli, John C. Panetta, Deborah A. Ward, Clinton F. Stewart, James M. Hoffman, Scott C. Howard, Ching‐Hon Pui, Alberto S. Pappo, Mary V. Relling, Kristine R. Crews
Cancer.2012; 118(17): 4321. CrossRef

8,437 View
62 Download
3 Crossref

Treatment Result of Pediatric Osteosarcoma with Intraarterial Cisplatin: Hyoung Soo Choi, Hyoung Jin Kang, Jun Ah Lee, Hyo Heong Han, Hyeon Jin Park, Eun Sun Yoo, Woo Sun Kim, Hee Young Shin, In One Kim, Sang Hoon Lee, Hyo Seop Ahn, Han Koo Lee; J Korean Cancer Assoc. 1998;30(1):169-177.

Abstract PDF: PURPOSE
This study was performed to determine the outcome after treatment of osteosarcoma with intraarterial cisplatin as a preoperative chematherapy regimen.
MATERIALS AND METHODS
Twenty five patients with extremity osteosarcoma were treated with intraarterial cisplatin at Seoul National University Children's Hospital from January 1987 to April 1996. The dose of cisplatin was 130 mg/m2 and three to six courses were repeated two- to three-week intervals, Systemic doxorubicin was added to six of these patients. This was followed by surgical resection(limb salvage or amputation) and postoperative adjuvant chemotherapy.
RESULTS
Limb-salvage was possible in twenty of these twenty five patients. Pulmonary metastasis was present in five patients at diagnosis and developed later in three patients. In six patients treated with systemic doxorubicin, pulmonary metastasis was absent at diagnosis and during follow-up period. Local recurrence after limb salvage was occurred in one patient and treated with amputation and systemic chemotherapy. Seven patients died from pulmonary metastssis and one from unknown cause. The follow-up duration of these patients was three to eighty eight months(median twenty two months) and the overall five-year survival and event free survival rate were 62.1% and 57.5%, respectively.
CONCLUSION
These data demonstrate that intraarterial cisplatin can be used as an effective regimen preoperatively for pediatric patients with extremity osteosarcoma. The combined use of systemic doxorubicin is expected to improve survival in patients with pulmonary metastasis.

3,153 View
15 Download

A Study on Cancer Frequent Families and Their Hereditary Tendency: Minyoung Kim, Soo Tae Kim, Jin Pok Kim, Kwi Won Park, Hyo Seop Ahn, Seung Keun Oh, Kyk Jin Choe, Kyu Joo Park, Jae Hwan Oh, Jae Gagb Park; J Korean Cancer Assoc. 1995;27(5):857-869.

Abstract PDF: Authors have defined "Cancer Frequent Family (CFF)" as a family that yresents with clustering of different types of cancers among its members, but does not satisfy the arite- ria of any known hereditary cancer syndromes. The inclusion criteria for CFF are: three or more cancer patients (1) among siblings or (2) in more tbsn two successive generations or (3) in 3 or more cousins, with at least one of the patients diagnosed before the age of 50. Gastric cancer after age of 45 and primary liver cancer were excluded. By screening family history of cancer patients admitted to Seoul National University Hospital since l992, nine families fulfiling the CFF criteria were identified. Among 294 family members from these 9 families, thirty-six(12%) were affected with cancer. A total of 41 primary cancers affecting 10 different organs were found, with the average age at diaenosis of the first primary cancer being 47. Five members were affected with double primary cancers; four with 2 colorectal cancers and one with a rectal cancer and a malignant thymoma. Colorectal cancer was by far the most common malignancy encountered, accounting for 5l% of all the malignancies found. The average age at diagnosis of colorectal cancers in CFF was significantly younger than that of sporedic cases(43 vs 56, P<0.01). The incidence of metachronous colorectal cancer was aleo high(24%) in this group. On the basis of familial aggregation, younger age of onset, and multiplicity of tumors in affected individuals, hereditary backgrounds can be suspected in colorectal cancer patients of CFF families. Our resuits indicate that clustering of different malignancies in a family may suggest possible hereditary causes and that regular screening may aid in the early detection of other affected individuals in CFF families

2,408 View
13 Download

Effects of cancer nervous System Irradiation on Neuropsychologic Functioning in Long - term Survivors of Childhood Acute Lymphoblastic Leukemia: Ji Eun Choi, Hee Young Shin, In One Kim, Kyung Mo Yeon, In Young Chae, Soo Churl Cho, Yong Seung Hwang, Hyo Seop Ahn; J Korean Cancer Assoc. 1995;27(2):303-316.

Abstract PDF: Long-term adverse neuropsychologic sequelae are frequently observed in pediatric patients treated for acute lymphoblastic leukemia(ALL). In this study, 10 children in continuous com- plete remission from ALL were given tests of IQ, neuropsychologic assessment, waking EEG, brain MRI to assess neuropsychologic functioning minimum 2 years after CNS prophylaxis. All children were free of CNS disease at diagnosis and had received CNS prophylactic treatment with 1,800 cGy cranial irradiation plus intrathecal methotrexate. Male patients had a significant decline in coding compared with female patients(P<0.01) and those evaluated beyond age of 10-year-old had a greater decline in performance IQ compared with those evaluated under age of 10-year-old(P<0.01). One of the 10 children(10%) showed white matter changes on MRI attributable to therapy. All children had no significant lower mean IQ, but lower achievement with regard to arithmetic skills, picture arrangement than other tests. We conclude that prophylactic CNS therapy may cause cognitive dysfunctions and the white matter changes but its value and significance during follow-up should be assessed in well designed longitudinal research studies.

2,751 View
13 Download

Effect of Filgrastim ( rhG - CSF ) on Chemotherapy Induced Neutropenia in Pediatric Acute Myelogenous Leukemia Patients: Hee Young Shin, Hee Young Shin, Seong Hoon Hah, Hong Hoe Koo, Hyo Seop Ahn; J Korean Cancer Assoc. 1994;26(1):136-144.

Abstract PDF: To determine the safety and efficacy of rhG-CSF on chemotherapy induced neutropenia in pediatric AML patients, we conducted a prospective controlled study in 17 patiens with AML at Seoul National University Childrens Hospital from July, 1993 to January, 1994. High dose cytosine arabinoside(Ara-C, 3gm/m for four times every 12 hours) with L-asparaginase 6,000 u/m) were given to 13 patients as Group I control and after the recovery of WBC, same chemo- therapy followed by G-CSF(50 ug/m for 10 days) were given as Group I study. In Group II study, high dose Ara-C(3gm/m(2) for 8 times every 12 hours) were given to 11 patients with AML followed by G-CSF(150 ug/m for 10 days). Recovery of the absolute neutrophil counts to more than 1,000/mm' was significantly faster in the G-CSF group than in the control group(P< 0.01) and the absolute neutrophil counts on day 14 of chemotherapy was significantly higher in G-CSF group(P<0.01). The toxicity of G-CSF was minimal and there was no evidence of accel- erated growth of leukemic blasts during the G-CSF treatment. In conclusion, Filgrastim(rhG- CSF) promotes the recovery of neutrophils and shortens the duration of neutropenia induced by the chemotherapy in pediatric acute myelogenous leukemia.

2,696 View
21 Download

Study on the treatment of childhood acute lymphoblastic leukemia: Sang Oh Na, Hee Young Shin, Hyo Seop Ahn, Sang Kyu Park; J Korean Cancer Assoc. 1992;24(3):390-400.

Abstract PDF: No abstract available.

2,190 View
14 Download

Treatment of Childhood Acute Lymphoblastic Leukemia Diagnosed Jan . , 1978 Through Dec . , 1987 : Comparison between Standard - Risk and High - Risk Groups: Soon Ki Kim, Hee Young Shin, Hyo Seop Ahn; J Korean Cancer Assoc. 1990;22(3):539-549.

Abstract PDF: Of 328 children who were diagnosed as acute lymphoblastic leukemia at the Department of Pediatrics. Seoul National University Hospital from Jan., 1978 through Dec., 1987, 211 patients above one year af age were evaluable for induction chemotherapy. The leukemias were classified as standard risk (SR), comparison group (who had high-risk prognostic factors, but had been treated with standard regimen), or high- risk (HR) leukemia according to the prognostic criteria at diagnosis. Three regimens were compared and the results were as follows. 1) The complete remission (CR) rate was 97.1%(133/137), 81.0%(34/42) and 90.6%(29/32) in SR, comparison group. and HR group, respectively. And significant difference in the CR rate was seen between SR group and comparison group (p= 0.0001). 2) Of the patients remained in remission follow-up of each group showed 56.8% 5-yr disease-free survival (DFS)(+-5.9%, median follow-up 30 mo) in SR, 35.5% (+-9.1%, median 24 mo) in comparison group, and 76.0%(+- 8.5%, median 24 mo) in HR group. And significant difference in the 5yr-DFS rate were observed be(ween SR and comparison group (P = 0.007), between HR and comparison group (p = 0.002), respectively. 3) Induction failure was due to infection (n=2) bleeding (n=1) or uric acid nephropathy (n= 1) in SR drug resistance (n=3), infection (n=2), bleeding (n=2), or combind infection and bleeding (n=1) in comparison group, and bleeding (n=2) or infection (n= 1) in HR. Of the patients who were on maintenance chemotherapy in complete remission, 11 died due to infection: menigitis or meningoencephalitis (n=4), disseminated varicella (n=3), Pneumocystis carinii pneumonia (n=2), and sepsis (n=2). 4) In SR group, 29 patients experienced relapse: BM(n=18), CNS(n=3), BM and CNS(n=4), and testes (n=4). Two- third (n = 19) of them relapsed between 6mo to 2yr after initial remission. In comparison graup, 20 relapsed: BM (n= 10), CNS(n=2), BM and CNS (n=3), testes (n=4), and testes and CNS(n =1), Mostly they relapsed within the first 2 years after remission. In HR group, all patients (BM 3 and CNS 1) experienced relapse from 1 yr to 1 1/2 yr after initial remission.

2,223 View
15 Download

Author index